Differential induction of serum interleukin-6 and -12 by interferon-α and -β administration in chronic hepatitis C patients

Hepatology Research

Volumn 27, Issue 2, 2003, Pages 101-108

  Kido, Miyoshi ^a   Kumagai, Naoki ^b   Toda, Kyoko ^c   Tsuchimoto, Kanji ^b   Komiyama, Takako ^a  

^a KITASATO UNIVERSITY   (Japan)

^b Research Center for Liver Disease   (Japan)

^c KITASATO INSTITUTE HOSPITAL   (Japan)

Author keywords

Chronic hepatitis C; Fever; Interferon ; Interferon ; Interleukin 12; Interleukin 6

Indexed keywords

ALPHA INTERFERON; ALPHA2A INTERFERON; ALPHA2B INTERFERON; BETA INTERFERON; INDOMETACIN; INTERLEUKIN 12; INTERLEUKIN 6;

ADULT; ARTICLE; BLOOD SAMPLING; BODY TEMPERATURE; CLINICAL ARTICLE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOKINE PRODUCTION; DRUG RESPONSE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEPATITIS C; HUMAN; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; STATISTICAL ANALYSIS;

EID: 0142180071     PISSN: 13866346     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1386-6346(03)00200-6     Document Type: Article

References (26)

1. Hayashi J, Ohmiya M, Kishihara Y, et al. A statistical analysis of predictive factors of response to human lymphoblastoid interferon in patients with chronic hepatitis C. Am J Gastroenterol 1994;89:2151-6.
2. Furusyo N, Hayashi J, Ueno K, et al. Human lymphoblastoid interferon treatment for patients with hepatitis C virus-related cirrhosis. Clin Ther 1997;19:1352-67.
3. Davis GL, Balart LA, Schiff ER, et al. Treatment of chronic hepatitis C with recombinant interferon alfa: a multicenter randomized, controlled trial. New Engl J Med 1989;321:1501-6.
4. Di Bisceglie AM, Martin P, Kassiandes C, et al. Recombinant interferon alfa therapy for chronic hepatitis C: a randomized, double-blind, placebo-controlled trial. New Engl J Med 1989;321:1506-10.
5. Nishiguchi S, Kuroki T, Nakatani S, et al. Randomised trial of effects of interferon-α on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis. Lancet 1995;346:1051-5.
6. Okushin H, Morii K, Kishi F, Yuasa S. Efficacy of the combination therapy using twice-a-day IFN-α followed by IFN-α2b in treatment for chronic hepatitis C. Acta Hepatol Jpn 1997;38:11-8.
7. Stern AS, Podlaski FJ, Hulmes JD, et al. Purification to homogeneity and partial characterization of cytotoxic lymphocyte maturation factor from human B-lymphoblastoid cells. Proc Natl Acad Sci USA 1990;87:6808-12.
8. Gubler U, Chua AO, Schoenhaut DS, et al. Coexpression of two distinct genes is required to generate secreted bioactive cytotoxic lymphocyte maturation factor. Proc Natl Acad Sci USA 1991;88:4143-7.
9. Kobayashi M, Fitz L, Ryan M, et al. Identification and purification of natural killer cell stimulatory factor (NKSF), a cytokine with multiple biologic effects on human lymphocytes. J Exp Med 1989;170:827-45.
10. D'andrea A, Rengaraju M, Valiante NM, et al. Production of natural killer cell stimulatory factor (interleukin 12) by peripheral blood mononuclear cells. J Exp Med 1992;176:1387-98.
11. Chan SH, Perussia B, Gupta JW, et al. Induction of interferon γ production by natural killer cell stimulatory factor: characterization of the responder cells and synergy with other inducers. J Exp Med 1991;173:869-79.
12. Trinchieri G. Interleukin-12 and its role in the generation of Th1 cells. Immunol Today 1993;14:335-8.
13. Trinchieri G. Interleukin-12: a cytokine produced by antigen-presenting cells with immunoregulatory functions in the generation of T-helper cells type 1 and cytotoxic lymphocytes. Blood 1994;84:4008-27.
14. Ohzato H, Monden M, Yoshizaki K, et al. Systemic production of interleukin-6 following acute inflammation. Biochem Biophys Res Commun 1993;197:1556-62.
15. Quiroga JA, Martin S, Navas S, Carreno V. Induction of interleukin-12 production in chronic hepatitis C virus infection correlates with the hepatocellular damage. J Infect Dis 1998;178:247-51.
16. Malaguarnera M, Di Fazio I, Laurino A, Ferlito L, Romano M, Trovato BA. Serum interleukin 6 concentrations in chronic hepatitis c patients before and after interferon-α treatment. Int J Clin Pharmacol Ther 1997;35:385-8.
17. Castell JV, Andus T, Kunz D, Heinrich PC. Interleukin-6: the major regulator of acute-phase protein synthesis in man and rat. Ann New York Acad Sci 1989;557:87-99.
18. Wysocka M, Kubin M, Vieira LQ, et al. Interleukin-12 is required for interferon-γ production and lethality in lipopolysaccharide-induced shock in mice. Eur J Immunol 1995;25:672-6.
19. Cacciarelli TV, Martinez OM, Gish RG, Villanueva JC, Krams SM. Immunoregulatory cytokines in chronic hepatitis c virus infection: pre- and posttreatment with interferon alfa. Hepatology 1996;24:6-9.
20. Uetake T, Akahane Y, Kume S, Ito M. Interleukin 12 (IL-12) production and its relations to other cytokines in patients with chronic hepatitis C. Hepatol Res 1999;15:238-51.
21. Kishimoto T. The biology of interleukin-6. Blood 1989;74:1-10.
22. Ito N, Kawata S, Tamura S, et al. Induction of interleukin-6 by interferon alfa and its abrogation by a serine protease inhibitor in patients with chronic hepatitis c. Hepatology 1996;23:669-74.
23. Jiang H, Dhib-Jalbut S. Differential induction of IL-12 by IFN-β and IFN-γ in human macrophages. J Interferon Cytokine Res 1998;18:697-703.
24. Fang SH, Hwang LH, Chen DS, Chiang BL. Ribavirin enhancement of hepatitis C virus core antigen-specific type 1 T heper cell response correlates with the increased IL-12 level. J Hepatol 2000;33:791-8.
25. Tam RC, Pai B, Bard J, et al. Ribavirin polarizes human T cell responses towards a type 1 cytokine profile. J Hepatol 1999;30:376-82.
26. Barnes E, Harcourt G, Brown D, et al. The dynamics of T-lymphocyte responses during combination therapy for chronic hepatitis C virus infection. Hepatology 2002;36:743-54.